Helios Klinikum Emil von Behring

Berlin 14165

0 studies enrolling now · 11 studies all time

What they study most

ALK-positive Advanced NSCLC, Adenocarcinoma of the Lung, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small-Cell Lung, Fibrosis, Idiopathic Interstitial Pneumonias, Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, Malignant Pleural Mesothelioma, Mesothelioma, Pathologic Processes

Studies at this site

• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer — Running, not enrolling
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment — Completed
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis — Stopped early
• An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung — Completed
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study — Completed